Cargando…

A closer look at the baseline-observation-carried-forward (BOCF)

PURPOSE: The baseline-observation-carried-forward (BOCF) approach is one method to handle missing data from early treatment discontinuation. We examined modifications of this approach, taking into consideration treatment-related and nontreatment-related reasons for discontinuation. METHODS: Two dulo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu-Seifert, Hong, Zhang, Shuyu, D’Souza, Deborah, Skljarevski, Vladimir
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819899/
https://www.ncbi.nlm.nih.gov/pubmed/20165594
_version_ 1782177327948496896
author Liu-Seifert, Hong
Zhang, Shuyu
D’Souza, Deborah
Skljarevski, Vladimir
author_facet Liu-Seifert, Hong
Zhang, Shuyu
D’Souza, Deborah
Skljarevski, Vladimir
author_sort Liu-Seifert, Hong
collection PubMed
description PURPOSE: The baseline-observation-carried-forward (BOCF) approach is one method to handle missing data from early treatment discontinuation. We examined modifications of this approach, taking into consideration treatment-related and nontreatment-related reasons for discontinuation. METHODS: Two duloxetine chronic pain trials (placebo-controlled) were used to examine the impact of different analytical methods on study outcome. Reasons for discontinuation were categorized as treatment-related and nontreatment-related. Missing data in the primary efficacy outcome were handled using five statistical methods: mixed-model repeated measures (MMRM), last-observation-carried-forward (LOCF), BOCF, modified BOCF (mBOCF, discontinuation due to treatment-related reasons, ie, adverse events [AEs] or lack of efficacy), and aeBOCF (discontinuation due to AEs only). RESULTS: Duloxetine was superior to placebo on mean change from baseline in Brief Pain Inventory average pain rating, using MMRM (study 1, P = 0.004; study 2, P < 0.001), LOCF (study 1, P = 0.019; study 2, P < 0.001), BOCF (study 1, P = 0.019; study 2, P = 0.013), and mBOCF (study 1, P = 0.041; study 2, P = 0.005). Using aeBOCF, duloxetine was superior to placebo in study 2 (P = 0.005) and numerically better in study 1 (P = 0.075). CONCLUSION: Due to the different assumptions made by various methods regarding accounting for missing data, the analytical methods chosen may influence the interpretation of study results. Consideration should be given to the effect of actual treatment outcomes from patients. Employing different statistical approaches such as sensitivity analyses may help to assess the robustness of the study results and provide a more accurate reflection of the treatment outcome.
format Text
id pubmed-2819899
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28198992010-02-17 A closer look at the baseline-observation-carried-forward (BOCF) Liu-Seifert, Hong Zhang, Shuyu D’Souza, Deborah Skljarevski, Vladimir Patient Prefer Adherence Original Research PURPOSE: The baseline-observation-carried-forward (BOCF) approach is one method to handle missing data from early treatment discontinuation. We examined modifications of this approach, taking into consideration treatment-related and nontreatment-related reasons for discontinuation. METHODS: Two duloxetine chronic pain trials (placebo-controlled) were used to examine the impact of different analytical methods on study outcome. Reasons for discontinuation were categorized as treatment-related and nontreatment-related. Missing data in the primary efficacy outcome were handled using five statistical methods: mixed-model repeated measures (MMRM), last-observation-carried-forward (LOCF), BOCF, modified BOCF (mBOCF, discontinuation due to treatment-related reasons, ie, adverse events [AEs] or lack of efficacy), and aeBOCF (discontinuation due to AEs only). RESULTS: Duloxetine was superior to placebo on mean change from baseline in Brief Pain Inventory average pain rating, using MMRM (study 1, P = 0.004; study 2, P < 0.001), LOCF (study 1, P = 0.019; study 2, P < 0.001), BOCF (study 1, P = 0.019; study 2, P = 0.013), and mBOCF (study 1, P = 0.041; study 2, P = 0.005). Using aeBOCF, duloxetine was superior to placebo in study 2 (P = 0.005) and numerically better in study 1 (P = 0.075). CONCLUSION: Due to the different assumptions made by various methods regarding accounting for missing data, the analytical methods chosen may influence the interpretation of study results. Consideration should be given to the effect of actual treatment outcomes from patients. Employing different statistical approaches such as sensitivity analyses may help to assess the robustness of the study results and provide a more accurate reflection of the treatment outcome. Dove Medical Press 2010-02-04 /pmc/articles/PMC2819899/ /pubmed/20165594 Text en © 2010 Liu-Seifert et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Liu-Seifert, Hong
Zhang, Shuyu
D’Souza, Deborah
Skljarevski, Vladimir
A closer look at the baseline-observation-carried-forward (BOCF)
title A closer look at the baseline-observation-carried-forward (BOCF)
title_full A closer look at the baseline-observation-carried-forward (BOCF)
title_fullStr A closer look at the baseline-observation-carried-forward (BOCF)
title_full_unstemmed A closer look at the baseline-observation-carried-forward (BOCF)
title_short A closer look at the baseline-observation-carried-forward (BOCF)
title_sort closer look at the baseline-observation-carried-forward (bocf)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819899/
https://www.ncbi.nlm.nih.gov/pubmed/20165594
work_keys_str_mv AT liuseiferthong acloserlookatthebaselineobservationcarriedforwardbocf
AT zhangshuyu acloserlookatthebaselineobservationcarriedforwardbocf
AT dsouzadeborah acloserlookatthebaselineobservationcarriedforwardbocf
AT skljarevskivladimir acloserlookatthebaselineobservationcarriedforwardbocf
AT liuseiferthong closerlookatthebaselineobservationcarriedforwardbocf
AT zhangshuyu closerlookatthebaselineobservationcarriedforwardbocf
AT dsouzadeborah closerlookatthebaselineobservationcarriedforwardbocf
AT skljarevskivladimir closerlookatthebaselineobservationcarriedforwardbocf